Scarica l'app Stockscreener
11.16
1.36%
0.15
Dopo l'orario di chiusura:
10.95
-0.21
-1.88%
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
Merus Raises $300m After ASCO Success - insights.citeline.com
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Cantor Fitzgerald maintains overweight rating on Bicara stock By Investing.com - Investing.com India
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target - TipRanks
Cantor Fitzgerald maintains overweight rating on Bicara stock - Investing.com
Stifel reiterates Buy rating on Bicara Therapeutics stock - Investing.com Australia
Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com India
Bicara Responds to Rival Merus With Early Survival Data at #ASCO25 - BioSpace
Cantor Fitzgerald reiterates overweight rating on Bicara Therapeutics stock - Investing.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara presents promising early-stage data in head and neck cancers - The Business Journals
Bicara Therapeutics Reports Promising Phase 1/1b Trial Results for Ficerafusp Alfa in HPV-Negative Head and Neck Cancer - Nasdaq
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus ... - Enidnews.com
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 - GlobeNewswire Inc.
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients - MSN
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - Insider Monkey
Bicara Therapeutics Inc. (NASDAQ:BCAX) Shares Bought by Millennium Management LLC - Defense World
PIZZA PIZZA ROYALTY CORP. ANNOUNCES MAY DIVIDEND and TIMING OF ANNUAL GENERAL MEETING - The Globe and Mail
159,043 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Northern Trust Corp - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Raised to Equal Weight at Wells Fargo & Company - Defense World
Stifel maintains Bicara stock Buy rating, $48 target post-ASCO - Investing.com Australia
Stifel maintains Bicara stock Buy rating, $48 target post-ASCO By Investing.com - Investing.com Canada
112,476 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Deutsche Bank AG - Defense World
Bicara falls after early-stage trial data for head and neck cancer therapy - MSN
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics - MSN
Bicara Therapeutics (NASDAQ:BCAX) Stock Rating Lowered by Wall Street Zen - Defense World
Wells Fargo Upgrades Bicara Therapeutics (BCAX) - Nasdaq
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? - Benzinga
Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity (NASDAQ:BCAX) - Seeking Alpha
Biotech Soars On 'Unprecedented' Results, Slamming Its Rival - Investor's Business Daily
Wells Fargo Upgrades Bicara Therapeutics to Equal Weight From Underweight, $8 Price Target - marketscreener.com
Bicara Therapeutics upgraded to Equal Weight from Underweight at Wells Fargo - TipRanks
Wells upgrades Bicara to Equal Weight with thesis played out - TipRanks
Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook - Benzinga
Bicara stock falls after data for lead drug (BCAX:NASDAQ) - Seeking Alpha
Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results - Benzinga
Why Is Bicara Therapeutics Stock (BCAX) Down 30% Today? - TipRanks
Ross Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating - TipRanks
Promising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics - TipRanks
Bicara Therapeutics to present head and neck cancer study data - Investing.com Australia
ASCO25 abstract roundup: Roche's Itovebi cuts risk of death; Merus' bispecific impresses in HNSCC, while Bicara's disappoints - FirstWord Pharma
Bicara Therapeutics publishes updated data from Phase 1/1b trial of Ficerafusp - TipRanks
Bicara Therapeutics to present head and neck cancer study data By Investing.com - Investing.com Nigeria
Bicara Therapeutics stock tumbles on clinical trial data - Investing.com Australia
Bicara Therapeutics stock tumbles on clinical trial data By Investing.com - Investing.com Nigeria
Bicara Therapeutics Inc. Announces Updated Interim Data from Phase 1/1b Trial of Ficerafusp Alfa in Head and Neck Cancer Ahead of ASCO Presentation - Nasdaq
Bicara Therapeutics Announces Publication of an Abstract - GlobeNewswire
Micro-Cap Tech Firm Reports Triple-Digit Revenue Growth as Shares Climb - The Globe and Mail
Research Analysts Set Expectations for BCAX FY2026 Earnings - Defense World
TD Cowen reiterates Buy on Bicara Therapeutics stock - Investing.com Australia
0.00%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):